Tal Behar, Executive Director, Silicom Ventures

Currently, Tal leads the Personalized Medicine World Conference (PMWC), which provides a platform to foster collaboration among key stakeholders from business, government, healthcare-delivery, research and technology fields in order to catalyze change in healthcare delivery to patients in the US and around the globe. Tal is also the executive director of Silicom Ventures and has extensive experience in event organization and production. Under her leadership, Silicom Ventures launched over 150 high technology events located in Silicon Valley and abroad. Tal was instrumental in growing Silicom Ventures from 25 to over 250 members. Prior to Silicom Ventures Tal was a Law student at Tel Aviv University in Israel. Previously she was a senior officer in the IDF for over three years.

Marc Perlman, Global Vice President, Oracle Healthcare and Life Sciences

Marc Perlman is responsible for driving strategy and industry solutions across the organization. He leads the Healthcare Customer Industry Strategy Council, serves as executive lead with some of the top healthcare and life science companies, and integrally works with customers and partners to drive strategic initiatives. With more than 30 years in the healthcare industry, he brings deep global experience in working with payers, providers, health and device manufacturers, consumers, and governments to improve operational performance, clinical quality, patient safety, and revenue cycle performance. Mr. Perlman joined Oracle from McKesson Corporation in 2007, where over his 13-year tenure he progressed through operational and sales leadership roles in its provider technology solutions, health solutions, and medication safety/automation businesses. Prior to McKesson, he held executive roles within healthcare organizations focused on analytics, clinical services, and innovative disease management programs. Currently, Marc serves as a board member of the HIMSS Center for Patient and Family Centered Care and has served as a board member of the Continua Alliance, a nonprofit, open industry organization of healthcare and technology companies joining together in collaboration to improve the quality of connected healthcare.

Rivka Carmi, M.D., President of Ben Gurion University,

Prof. Rivka Carmi is an Israeli pediatrician and geneticist who, since May 2006, has served as President of Ben-Gurion University of the Negev. She is the first woman to be appointed president of an Israeli university.Born in Israel, she is a graduate of Hadassah Medical School of the Hebrew University of Jerusalem and did a two-year fellowship in medical genetics at Boston Children’s Hospital and Harvard University Medical School. She is the incumbent of the Kreitman Foundation Chair in Pediatric Genetics. Professor Carmi served as Director of the Genetics Institute at the Soroka University Medical Center and held several important academic administrative positions in the Faculty of Health Sciences at Ben-Gurion University of the Negev. Promoted to full professor in 1995, she is the incumbent of the Kreitman Foundation Chair in Pediatric Genetics. In 2000, she was elected Dean of the Faculty of Health Sciences at BGU – also the first woman to hold this position in Israel – and served in that position for five years. Between 2002 – 2005, she also served as the Chairperson of the Israeli Association of Medical Deans.

Michael Hayden, M.D., Ph.D., President, Global R&D and Chief Scientific Officer, Teva

Dr. Hayden has international standing as a research scientist and clinician. He has an outstanding record of leadership, innovation, and is a clinician-scientist who has spent his entire working life in research that has led directly to medicines which have made a substantial difference to patients around the world. His work in genetics and personalized medicine is internationally renowned, and he is one of the world’s leading experts on Huntington’s disease.

Dr. Hayden also has extensive experience in all stages of medicine development – from target identification, through the complete cycle of clinical development, to submission and approval processes with regulators around the world.

Currently, he is Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Director/Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.

Dr. Hayden has founded three biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; and Xenon Pharmaceuticals Inc. In 2011, he was awarded the Canada Gairdner Wightman award, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. In 2010, he was awarded the Order of Canada, which is the highest honour that Canada can give its citizens for exceptional achievement, merit or service.

In 2008 he was named Canada's Health Researcher of the Year and in 1998 received the Distinguished Scientist Award of the Canadian Society of Clinical Investigation. These are just some of the array of major honors and awards that demonstrate the esteem in which he is held internationally.